Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research

Data has been removed due to this being a sample, to access the paid version please contact us!
Global Retinopathy Of Prematurity Therapeutics Market Report 2023
2
Who Do
We Serve
Company
Strategy
Who We Are
What Do
We Do
Cognitive is a global leader
in research market business
and consulting. Publishing
more than a 100 research
studies every month, we
serve more than half of the
Fortune 500 companies
across the world. We, at
CMR, can help you with
multi-client reports,
company data profiles,
bases, procurement
intelligence, and custom
research services.
We at CMR, cover almost all
business verticals, including
chemicals, advanced materials,
agriculture, biotechnology,
industrial automation, medical
devices, mining, minerals,
metals, packaging,
pharmaceuticals, electronics,
telecommunications, IT,
aerospace and defense, food
and beverage and construction,
and building, and energy and
power.
We are not only a publisher of the
syndicate report but we also
provide the industry database and
respective topic's consultation. We,
at CMR, make all efforts to ensure
that our reports cover all aspects of
our industry. The Report
Customization along with a
dedicated research analyst access
puts us in a business category
where none of our competitors are
present.
We are the trusted business
partners to the world's leading
corporations, governments, and
institutions/universities. We also
have 1000+ client organizations
across the private, public and
social sectors. Client list ranges
from small and start-up
businesses to fortune 500
companies. Our client base
extends across Asia, North South
America, America, Europe,
Australia and Africa to know
more please refer to our cilentele
and testimony page on the
website.
COGNITIVE is the global leader in market research and business
consulting. We have been publishing more than a 250 research
studies every month we serve more than half of the Fortune 500
companies across the globe. We at COGNITIVE can help you with
multi-client reports, company profiles, data bases, procurement
intelligence and custom research services.
We at COGNITIVE cover almost all business verticals including chemicals,
advanced materials, agriculture, biotechnology, industrial automation,
medical devices, mining, minerals, metals, packaging, pharmaceuticals,
electronics, telecommunications, IT, aerospace and defense, food and
beverage and construction and building, and energy and power. While most
syndicated reports are standardized, we at COGNITIVE make all efforts to
ensure that our reports cover all aspects of the industry giving our customers
a holistic view of the industry COGNITIVE is backed by more than 120 analysts
and over 3000 industry experts, consultants and freelancers globally. We cover
more than 15 industry sectors in over 100 countries around the world. Please
feel free to let us know in case you need a deeper dive in any of the sections
mentioned in the report and one of our consultants will be happy to respond
back to you. © 2023 COGNITIVE Market Research.
About
Cognitive
Market Research

3
The base year for the calculation is 2022 and 2018 to 2022 will be historical period. At the same time, data
for the year 2023 will be an estimated one while the forecasted data will be from year 2023 to 2030.
Historical Years
From 2018
Till 2022
Base Year
2022
Forecast Period
From 2023
Till 2030
Primary Research Methodology
Secondary Research Methodology
Market Size Estimation Methodology
Data Triangulation
Business Segment/ Overview:
Investment in Research and Development
Recent Developments:
Business Strategy
SWOT Analysis
Key Drivers, Restraints and Opportunities
Market Attractiveness Analysis for Each Segment and Region
PESTEL Analysis
Porter 5 Force’s Analysis
Value Chain Analysis
North America (United States, Canada, Mexico)
Europe (UK, France, Germany, Italy, Russia, Spain)
Asia Pacific (China, Japan, Korea, India, South East Asia)
South America (Brazil, Argentina, Colombia)
Middle East & Africa (GCC, Egypt, South Africa, Nigeria, Turkey)
1 2
4
3

4
Indication
• Extra-retinal
Fibrovascular
Proliferation
• Partial Retinal
Detachment
• Total Retinal
Detachment
Treatment Type End-User Regions
• Oxygen therapies
• Laser Surgery
• Cryotherapy
• anti-VEGF
• Biologics (e.g.
Bevacizumab)
• Hospitals
• Ophthalmic Clinics
• Ambulatory
Surgical Centers
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

5
1.1 Research Methodology...............................................................................................26
1.1.1 Primary Research........................................................................................................ 27
1.1.2 Modes of Primary Research:....................................................................................... 28
1.2 Secondary Research Methodology:.............................................................................28
1.3 Market Estimation......................................................................................................29
1.3.1 Top-Down Method ..................................................................................................... 30
1.3.2 Bottom-Up Method .................................................................................................... 30
1.3.3 Data Triangulation ...................................................................................................... 31
1.4 Questionnaire ............................................................................................................32
2.1 Global Retinopathy Of Prematurity Therapeutics Industry Introduction.......................34
2.2 Objectives of the Study...............................................................................................35
2.3 USP of the Report.......................................................................................................35
2.4 Who is this report for?................................................................................................36
2.5 Regional Fragmentation .............................................................................................36
2.6 Report Duration .........................................................................................................37
2.7 List of Stakeholders ....................................................................................................37
3.1 Global Retinopathy Of Prematurity Therapeutics Market, 2018 – 2030, (USD
Million)......................................................................................................................38
3.2 Global Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity
Analysis .....................................................................................................................39
3.3 Global Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth
Projection by Region (2023 - 2030)..............................................................................39
3.4 Global Retinopathy Of Prematurity Therapeutics Market: Snapshot ............................41
4.1 Product Overview and Scope of Retinopathy Of Prematurity Therapeutics
Market.......................................................................................................................43
4.2 Global Retinopathy Of Prematurity Therapeutics Revenue Market by Regions
(2018-2030)................................................................................................................43
4.2.1 North America Retinopathy Of Prematurity Therapeutics Status and Prospect
(2018-2030) ................................................................................................................ 44

6
4.2.1.1 North America Retinopathy Of Prematurity Therapeutics Value,
Absolute & Opportunity Analysis ....................................................................44
4.2.2 Europe Retinopathy Of Prematurity Therapeutics Status and Prospect (2018-
2030) .......................................................................................................................... 45
4.2.2.1 Europe Retinopathy Of Prematurity Therapeutics Value, Absolute &
Opportunity Analysis .......................................................................................46
4.2.3 Asia Pacific Retinopathy Of Prematurity Therapeutics Status and Prospect
(2018-2030) ................................................................................................................ 47
4.2.3.1 47
4.2.3.2 Asia Pacific Retinopathy Of Prematurity Therapeutics Value,
4.2.4 Latin America Retinopathy Of Prematurity Therapeutics Status and Prospect
(2018-2030) ................................................................................................................ 49
4.2.4.1 Latin America Retinopathy Of Prematurity Therapeutics Value,
4.2.5 Middle East and Africa Retinopathy Of Prematurity Therapeutics Status and
Prospect (2018-2030).................................................................................................. 50
4.2.5.1 Middle East and Africa Retinopathy Of Prematurity Therapeutics
Value, Absolute & Opportunity Analysis .........................................................51
4.3 Global Retinopathy Of Prematurity Therapeutics Market Size (2018-2030) ..................52
4.3.1 Global Retinopathy Of Prematurity Therapeutics Revenue Status and Outlook
(2018-2030) ................................................................................................................ 52
5.1 Global Retinopathy Of Prematurity Therapeutics Revenue and Share by
Manufacturers (2018-2022) ........................................................................................53
5.2 Global Retinopathy Of Prematurity Therapeutics Mergers and Acquisition
Analysis/ Top Winning Strategies/ New Launches Analysis ..........................................55
5.3 Company Categorization.............................................................................................56
5.4 Top Winning Strategies, by Manufacturers (2018-2022)...............................................57
6.1 Overall Company’s Disclosure Score............................................................................58
7.1 Global Retinopathy Of Prematurity Therapeutics Market – COVID – 19 Impact
Analysis .....................................................................................................................59
7.1.1 Influencing Factors...................................................................................................... 60
7.1.2 Forecast Assumptions................................................................................................. 60
7.1.3 Impact of COVID-19 on Global Retinopathy Of Prematurity Therapeutics
Market........................................................................................................................ 61

7
7.1.4 Consumer Buying Behavior on Global Retinopathy Of Prematurity
Therapeutics Market................................................................................................... 61
8.1 Market Drivers...........................................................................................................62
8.1.1 Drivers for Retinopathy Of Prematurity Therapeutics Market: Impact Analysis.......... 62
8.2 Market Restraints.......................................................................................................63
8.2.1 Restraints for Retinopathy Of Prematurity Therapeutics Market: Impact
Analysis ...................................................................................................................... 63
8.3 Opportunity ...............................................................................................................64
8.4 Market Trends............................................................................................................64
8.5 Technological Road Map.............................................................................................65
8.6 PESTEL Analysis for Retinopathy Of Prematurity Therapeutics Market.........................66
8.6.1 Political....................................................................................................................... 66
8.6.2 Economic .................................................................................................................... 66
8.6.3 Social .......................................................................................................................... 67
8.6.4 Technological.............................................................................................................. 67
8.6.5 Legal ........................................................................................................................... 67
8.6.6 Environmental ............................................................................................................ 67
8.7 Porter’s Five Forces Analysis for Retinopathy Of Prematurity Therapeutics
Market.......................................................................................................................68
8.7.1 Power of Suppliers...................................................................................................... 69
8.7.2 Threat of Substitutes .................................................................................................. 70
8.7.3 Potential of New Entrants into an Industry................................................................. 71
8.7.4 Power of Customers.................................................................................................... 72
8.7.5 Competition in the Industry........................................................................................ 73
8.8 Product Life Cycle of Retinopathy Of Prematurity Therapeutics Market .......................74
8.9 Market Attractiveness Analysis...................................................................................75
8.9.1 Market Attractiveness Analysis by Type Segment....................................................... 75
8.9.2 Market Attractiveness Analysis by Application Segment ............................................ 76
9.1 Industry chain analysis ...............................................................................................77
9.2 Manufacturing Cost Analysis.......................................................................................77
9.3 Consumer Preference Analysis....................................................................................77
9.4 Supply Side Analysis ...................................................................................................78

8
9.4.1 Raw Material Analysis ................................................................................................ 78
9.4.2 Raw Material Procurement Analysis ........................................................................... 78
9.4.3 Raw Material Price Trend Analysis.............................................................................. 79
10.1 Patent Analysis...........................................................................................................80
11.1 Global Retinopathy Of Prematurity Therapeutics Revenue and Market Share (%)
by Indication (2018-2030)...........................................................................................81
11.1.1 Extra-retinal Fibrovascular Proliferation ..................................................................... 83
11.1.1.1 Extra-retinal Fibrovascular Proliferation Retinopathy Of Prematurity
Therapeutics Value, Absolute & Opportunity Analysis....................................83
11.1.1.2 Retinopathy Of Prematurity Therapeutics Market for Extra-retinal
Fibrovascular Proliferation, by Country (2021 Vs 2024)..................................84
11.1.2 Partial Retinal Detachment......................................................................................... 85
11.1.2.1 Partial Retinal Detachment Retinopathy Of Prematurity Therapeutics
11.1.2.2 Retinopathy Of Prematurity Therapeutics Market for Partial Retinal
Detachment, by Country (2021 Vs 2024) ........................................................86
11.1.3 Total Retinal Detachment ........................................................................................... 87
11.1.3.1 Total Retinal Detachment Retinopathy Of Prematurity Therapeutics
11.1.3.2 Retinopathy Of Prematurity Therapeutics Market for Total Retinal
Detachment, by Country (2021 Vs 2024) ........................................................88
by Treatment Type (2018-2030)..................................................................................89
12.1.1 Oxygen therapies........................................................................................................ 91
12.1.1.1 Oxygen therapies Retinopathy Of Prematurity Therapeutics Value,
12.1.1.2 Retinopathy Of Prematurity Therapeutics Market for Oxygen
therapies, by Country (2021 Vs 2024) .............................................................92
12.1.2 Laser Surgery .............................................................................................................. 93
12.1.2.1 Laser Surgery Retinopathy Of Prematurity Therapeutics Value,
12.1.2.2 Retinopathy Of Prematurity Therapeutics Market for Laser Surgery,
by Country (2021 Vs 2024) ..............................................................................94

9
12.1.3 Cryotherapy................................................................................................................ 95
12.1.3.1 Cryotherapy Retinopathy Of Prematurity Therapeutics Value,
12.1.3.2 Retinopathy Of Prematurity Therapeutics Market for Cryotherapy, by
Country (2021 Vs 2024)...................................................................................96
12.1.4 anti-VEGF.................................................................................................................... 97
12.1.4.1 anti-VEGF Retinopathy Of Prematurity Therapeutics Value, Absolute
& Opportunity Analysis....................................................................................97
12.1.4.2 Retinopathy Of Prematurity Therapeutics Market for anti-VEGF, by
Country (2021 Vs 2024)...................................................................................98
12.1.5 Biologics (e.g. Bevacizumab)....................................................................................... 99
12.1.5.1 Biologics (e.g. Bevacizumab) Retinopathy Of Prematurity
Therapeutics Value, Absolute & Opportunity Analysis....................................99
12.1.5.2 Retinopathy Of Prematurity Therapeutics Market for Biologics (e.g.
Bevacizumab), by Country (2021 Vs 2024)....................................................100
by End-User (2018-2030) ..........................................................................................101
13.1.1 Hospitals................................................................................................................... 103
13.1.1.1 Hospitals Retinopathy Of Prematurity Therapeutics Value, Absolute
& Opportunity Analysis..................................................................................103
13.1.1.2 Retinopathy Of Prematurity Therapeutics Market for Hospitals, by
Country (2021 Vs 2024).................................................................................104
13.1.2 Ophthalmic Clinics .................................................................................................... 105
13.1.2.1 Ophthalmic Clinics Retinopathy Of Prematurity Therapeutics Value,
Absolute & Opportunity Analysis ..................................................................105
13.1.2.2 Retinopathy Of Prematurity Therapeutics Market for Ophthalmic
Clinics, by Country (2021 Vs 2024) ................................................................106
13.1.3 Ambulatory Surgical Centers..................................................................................... 107
13.1.3.1 Ambulatory Surgical Centers Retinopathy Of Prematurity
Therapeutics Value, Absolute & Opportunity Analysis..................................107
13.1.3.2 Retinopathy Of Prematurity Therapeutics Market for Ambulatory
Surgical Centers, by Country (2021 Vs 2024).................................................108
14.1 Bayer AG..................................................................................................................110
14.1.1 Bayer AG Basic Information, Manufacturing Base, SalesArea and its
Competitors.............................................................................................................. 110
14.1.2 Business Segment/ Overview:................................................................................... 111

10
14.1.3 Financials.................................................................................................................. 111
14.1.4 Investment in Research and Development................................................................ 112
14.1.5 Recent Developments:.............................................................................................. 113
14.1.6 Business Strategy...................................................................................................... 113
14.1.7 Management Change................................................................................................ 113
14.1.8 Bayer AG S.W.O.T Analysis ....................................................................................... 114
14.1.9 COVID-19 Impact Analysis......................................................................................... 114
14.2 D.Western Therapeutics Institute Hoffmann- La Roche Ltd........................................115
14.3 Regeneron Pharmaceutical Inc..................................................................................115
14.4 Insmed Inc ...............................................................................................................115
14.5 F. Hoffmann-La Rochelnc..........................................................................................115
14.6 Recordati SpA ..........................................................................................................115
14.7 Alimera Science Inc ..................................................................................................115
14.8 Biomar Microbial Technologies. etc ..........................................................................115
by Region (2018 - 2030) ............................................................................................117
16.1 North America Retinopathy Of Prematurity Therapeutics Market by Country,
(2018-2030)..............................................................................................................118
16.2 North America Retinopathy Of Prematurity Therapeutics Market Size (2018-
2030) .......................................................................................................................118
16.3 North America Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth
Projection by Country (2023-2030)............................................................................119
16.3.1 North America Retinopathy Of Prematurity Therapeutics Market Revenue
(USD Million) Size by Indication (2018-2030) ............................................................ 120
16.3.2 North America Retinopathy Of Prematurity Therapeutics Market Size by
Indication 2022 and 2030.......................................................................................... 120
(USD Million) Size by Treatment Type (2018-2030)................................................... 121
16.3.4 North America Retinopathy Of Prematurity Therapeutics Market Size by
Treatment Type 2022 and 2030 ................................................................................ 121
(USD Million) Size by End-User (2018-2030).............................................................. 122

11
16.3.6 North America Retinopathy Of Prematurity Therapeutics Market Size by End-
User 2022 and 2030 .................................................................................................. 122
16.4 United States ...........................................................................................................123
16.4.1 United States Retinopathy Of Prematurity Therapeutics Market Revenue
16.4.2 United States Retinopathy Of Prematurity Therapeutics Market Share by
Indication in 2022 ..................................................................................................... 123
16.4.4 United States Retinopathy Of Prematurity Therapeutics Market Share by
Treatment Type in 2022............................................................................................ 124
16.4.6 United States Retinopathy Of Prematurity Therapeutics Market Share by End-
User in 2022.............................................................................................................. 125
16.5 Canada.....................................................................................................................126
16.5.1 Canada Retinopathy Of Prematurity Therapeutics Market Revenue (USD
Million) Size by Indication (2018-2030)..................................................................... 126
16.5.2 Canada Retinopathy Of Prematurity Therapeutics Market Share % by
Indication in 2022 ..................................................................................................... 126
Million) Size by Treatment Type (2018-2030)............................................................ 127
16.5.4 Canada Retinopathy Of Prematurity Therapeutics Market Share % by
Treatment Type in 2022............................................................................................ 127
Million) Size by End-User (2018-2030) ...................................................................... 128
16.5.6 Canada Retinopathy Of Prematurity Therapeutics Market Share % by End-
User in 2022.............................................................................................................. 128
16.6 Mexico.....................................................................................................................129
16.6.1 Mexico Retinopathy Of Prematurity Therapeutics Market Revenue (USD
16.6.2 Mexico Retinopathy Of Prematurity Therapeutics Market Share by Indication
in 2022...................................................................................................................... 129
16.6.4 Mexico Retinopathy Of Prematurity Therapeutics Market Share by Treatment
Type in 2022 ............................................................................................................. 130

12
16.6.6 Mexico Retinopathy Of Prematurity Therapeutics Market Share by End-User
in 2022...................................................................................................................... 131
17.1 Europe Retinopathy Of Prematurity Therapeutics Market by Country, (2018-
2030) .......................................................................................................................132
17.2 Europe Retinopathy Of Prematurity Therapeutics Market Size (2018-2030) ...............133
17.3 Europe Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth
17.3.1 Europe Retinopathy Of Prematurity Therapeutics Market Revenue (USD
17.3.2 Europe Retinopathy Of Prematurity Therapeutics Market Size by Indication
2022 and 2030 .......................................................................................................... 134
17.3.4 Europe Retinopathy Of Prematurity Therapeutics Market Size by Treatment
Type 2022 and 2030.................................................................................................. 135
17.3.6 Europe Retinopathy Of Prematurity Therapeutics Market Size by End-User
2022 and 2030 .......................................................................................................... 136
17.4 United Kingdom .......................................................................................................137
17.4.1 United Kingdom Retinopathy Of Prematurity Therapeutics Market Revenue
and Share by Indication (2018-2030)......................................................................... 137
and Share by Treatment Type (2018-2030) ............................................................... 137
and Share by End-User (2018-2030).......................................................................... 137
17.5 France......................................................................................................................137
17.5.1 France Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 137
by Treatment Type (2018-2030)................................................................................ 137
by End-User (2018-2030)........................................................................................... 137
17.6 Germany..................................................................................................................137
17.6.1 Germany Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by Indication (2018-2030) ............................................................................... 137

13
Share by Treatment Type (2018-2030)...................................................................... 137
Share by End-User (2018-2030)................................................................................. 137
17.7 Italy .........................................................................................................................137
17.7.1 Italy Retinopathy Of Prematurity Therapeutics Market Revenue and Share by
Indication (2018-2030).............................................................................................. 137
Treatment Type (2018-2030) .................................................................................... 137
End-User (2018-2030) ............................................................................................... 138
17.8 Russia ......................................................................................................................138
17.8.1 Russia Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 138
by End-User (2018-2030)........................................................................................... 138
17.9 Spain........................................................................................................................138
17.9.1 Spain Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 138
by End-User (2018-2030)........................................................................................... 138
17.10 Sweden....................................................................................................................138
17.10.1 Sweden Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 138
by End-User (2018-2030)........................................................................................... 138
17.11 Denmark..................................................................................................................138
17.11.1 Denmark Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 139
17.12 Netherlands .............................................................................................................139

14
17.12.1 Netherlands Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 139
17.13 Switzerland..............................................................................................................139
17.13.1 Switzerland Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 139
17.14 Belgium....................................................................................................................139
17.14.1 Belgium Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 139
by End-User (2018-2030)........................................................................................... 139
17.15 Rest of Europe..........................................................................................................140
17.15.1 Rest of Europe Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 140
18.1 Asia Pacific Retinopathy Of Prematurity Therapeutics Market by Country, (2018-
2030) .......................................................................................................................141
18.2 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size (2018-2030) .........142
18.3 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth
18.3.1 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Revenue (USD
18.3.2 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by
Indication 2022 and 2030.......................................................................................... 143

15
18.3.4 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by
18.3.6 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by End-User
2022 and 2030 .......................................................................................................... 145
18.4 China .......................................................................................................................146
18.4.1 China Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 146
by End-User (2018-2030)........................................................................................... 146
18.5 Japan .......................................................................................................................146
18.5.1 Japan Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 146
by End-User (2018-2030)........................................................................................... 146
18.6 Korea.......................................................................................................................146
18.6.1 Korea Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 146
by End-User (2018-2030)........................................................................................... 146
18.7 India ........................................................................................................................147
18.7.1 India Retinopathy Of Prematurity Therapeutics Market Revenue and Share by
Indication (2018-2030).............................................................................................. 147
Treatment Type (2018-2030) .................................................................................... 147
End-User (2018-2030) ............................................................................................... 147
18.8 Australia ..................................................................................................................147
18.8.1 Australia Retinopathy Of Prematurity Therapeutics Market Revenue and

16
Share by End-User (2018-2030)................................................................................. 147
18.9 Philippines ...............................................................................................................147
18.9.1 Philippines Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 147
18.10 Singapore.................................................................................................................148
18.10.1 Singapore Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 148
18.11 Malaysia ..................................................................................................................148
18.11.1 Malaysia Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 148
18.12 Thailand...................................................................................................................148
18.12.1 Thailand Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 148
18.13 Indonesia.................................................................................................................149
18.13.1 Indonesia Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 149
18.14 Rest of APAC ............................................................................................................149

17
18.14.1 Rest of APAC Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 149
19.1 South America Retinopathy Of Prematurity Therapeutics Market by Country,
(2018-2030)..............................................................................................................150
19.2 South America Retinopathy Of Prematurity Therapeutics Market Size (2018-
2030) .......................................................................................................................150
19.3 South America Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth
19.3.1 South America Retinopathy Of Prematurity Therapeutics Market Revenue
19.3.2 South America Retinopathy Of Prematurity Therapeutics Market Size by
Indication 2022 and 2030.......................................................................................... 152
19.3.4 South America Retinopathy Of Prematurity Therapeutics Market Size by
19.3.6 South America Retinopathy Of Prematurity Therapeutics Market Size by End-
User 2022 and 2030 .................................................................................................. 154
19.4 Brazil .......................................................................................................................155
19.4.1 Brazil Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 155
by End-User (2018-2030)........................................................................................... 155
19.5 Argentina.................................................................................................................155
19.5.1 Argentina Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 155

18
19.6 Colombia .................................................................................................................155
19.6.1 Colombia Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 155
19.7 Peru.........................................................................................................................156
19.7.1 Peru Retinopathy Of Prematurity Therapeutics Market Revenue and Share by
Indication (2018-2030).............................................................................................. 156
Treatment Type (2018-2030) .................................................................................... 156
End-User (2018-2030) ............................................................................................... 156
19.8 Chile ........................................................................................................................156
19.8.1 Chile Retinopathy Of Prematurity Therapeutics Market Revenue and Share by
Indication (2018-2030).............................................................................................. 156
Treatment Type (2018-2030) .................................................................................... 156
End-User (2018-2030) ............................................................................................... 156
19.9 Rest of South America ..............................................................................................156
19.9.1 Rest of South America Retinopathy Of Prematurity Therapeutics Market
Revenue and Share by Indication (2018-2030).......................................................... 156
Revenue and Share by Treatment Type (2018-2030)................................................. 156
Revenue and Share by End-User (2018-2030) ........................................................... 156
20.1 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market by
Country, (2018-2030)................................................................................................157
20.2 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size
(2018-2030)..............................................................................................................157
20.3 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Y-o-Y
Growth Projection by Country (2023-2030) ...............................................................158
20.3.1 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market
Revenue (USD Million) Size by Indication (2018-2030).............................................. 159

19
20.3.2 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size
by Indication 2022 and 2030 ..................................................................................... 159
Revenue (USD Million) Size by Treatment Type (2018-2030) .................................... 160
by Treatment Type 2022 and 2030............................................................................ 160
Revenue (USD Million) Size by End-User (2018-2030) ............................................... 161
by End-User 2022 and 2030 ...................................................................................... 161
20.4 Saudi Arabia.............................................................................................................162
20.4.1 Saudi Arabia Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 162
20.5 Turkey .....................................................................................................................162
20.5.1 Turkey Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 162
by End-User (2018-2030)........................................................................................... 162
20.6 Nigeria.....................................................................................................................162
20.6.1 Nigeria Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 162
by End-User (2018-2030)........................................................................................... 162
20.7 UAE..........................................................................................................................163
20.7.1 UAE Retinopathy Of Prematurity Therapeutics Market Revenue and Share by
Indication (2018-2030).............................................................................................. 163
Treatment Type (2018-2030) .................................................................................... 163
End-User (2018-2030) ............................................................................................... 163
20.8 Egypt .......................................................................................................................163

20
20.8.1 Egypt Retinopathy Of Prematurity Therapeutics Market Revenue and Share
by Indication (2018-2030) ......................................................................................... 163
by End-User (2018-2030)........................................................................................... 163
20.9 South Africa .............................................................................................................163
20.9.1 South Africa Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 163
20.10 GCC Countries ..........................................................................................................164
20.10.1 GCC Countries Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 164
20.11 Rest of MEA .............................................................................................................164
20.11.1 Rest of MEA Retinopathy Of Prematurity Therapeutics Market Revenue and
Share by End-User (2018-2030)................................................................................. 164
21.1 Key Takeaways.........................................................................................................165
21.2 Analyst Point of View ...............................................................................................165

21
FIG. 1 Primary Research Method 27
FIG. 2 Market Research Process 28
FIG. 3 Source of Secondary Research 29
FIG. 4 Top-Down Method 30
FIG. 5 Bottom-Up Method 30
FIG. 6 Data Triangulation 31
FIG. 7 Global Retinopathy Of Prematurity Therapeutics Market, 2018 – 2030, (USD Million) 38
FIG. 8 Global Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis 39
FIG. 9 Global Retinopathy Of Prematurity Therapeutics Market, Y-o-Y Growth Projection (2023-2030) 39
FIG. 10 Global Retinopathy Of Prematurity Therapeutics Revenue Market Share (%) by Regions in 2018, 2022,
2030 43
FIG. 11 North America Retinopathy Of Prematurity Therapeutics Revenue (USD Million) and Growth Rate
(2018-2030) 44
FIG. 12 North America Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis 44
FIG. 13 Europe Retinopathy Of Prematurity Therapeutics Revenue (USD Million) and Growth Rate (2018-2030) 45
FIG. 14 Europe Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis 46
FIG. 15 Asia Pacific Retinopathy Of Prematurity Therapeutics Revenue (USD Million) and Growth Rate (2018-
2030) 47
FIG. 16 Asia Pacific Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis 48
FIG. 17 Latin America Retinopathy Of Prematurity Therapeutics Revenue (USD Million) and Growth Rate
(2018-2030) 49
FIG. 18 Latin America Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis 49
FIG. 19 Middle East and Africa Retinopathy Of Prematurity Therapeutics Revenue (USD Million) and Growth
Rate (2018-2030) 50
FIG. 20 Middle East and Africa Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity
Analysis 51
FIG. 21 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) Status and Outlook (2018-
2030) 52
FIG. 22 Global Retinopathy Of Prematurity Therapeutics Revenue Share by Manufacturers 54
FIG. 23 Top Winning Strategies, by Manufacturers (2018-2022) 57
FIG. 24 Overall Company’s Disclosure Score 58
FIG. 25 Global Retinopathy Of Prematurity Therapeutics Market – PESTEL Analysis 66
FIG. 26 Porter’s Five Forces Analysis 68
FIG. 27 Power of Suppliers 69
FIG. 28 Threat of Substitutes 70
FIG. 29 Potential of New Entrants into an Industry 71
FIG. 30 Power of Customers 72
FIG. 31 Competition in the Industry 73
FIG. 32 Product Life Cycle 74
FIG. 33 Market Attractiveness Analysis by Type Segment 75
FIG. 34 Market Attractiveness Analysis by Application Segment 76
FIG. 35 Value Chain Analysis of Retinopathy Of Prematurity Therapeutics Market 77
FIG. 36 2022 Revenue Market Share (%) of Retinopathy Of Prematurity Therapeutics by Indication 82
FIG. 37 Global Extra-retinal Fibrovascular Proliferation Market Revenue (USD Million) and Growth Rate (%),
(2018 – 2030) 83
FIG. 38 Global Extra-retinal Fibrovascular Proliferation Market Revenue (USD Million) and Growth Rate (%),
(2018 – 2030) 83
FIG. 39 Retinopathy Of Prematurity Therapeutics Market for Extra-retinal Fibrovascular Proliferation, by Country
(2021 Vs 2024) 84

22
FIG. 40 Global Partial Retinal Detachment Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 85
FIG. 41 Global Partial Retinal Detachment Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 85
FIG. 42 Retinopathy Of Prematurity Therapeutics Market for Partial Retinal Detachment, by Country (2021 Vs
2024) 86
FIG. 43 Global Total Retinal Detachment Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 87
FIG. 44 Global Total Retinal Detachment Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 87
FIG. 45 Retinopathy Of Prematurity Therapeutics Market for Total Retinal Detachment, by Country (2021 Vs
2024) 88
FIG. 46 2022 Revenue Market Share (%) of Retinopathy Of Prematurity Therapeutics by Treatment Type 90
FIG. 47 Global Oxygen therapies Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 91
FIG. 48 Global Oxygen therapies Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 91
FIG. 49 Retinopathy Of Prematurity Therapeutics Market for Oxygen therapies, by Country (2021 Vs 2024) 92
FIG. 50 Global Laser Surgery Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 93
FIG. 51 Global Laser Surgery Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 93
FIG. 52 Retinopathy Of Prematurity Therapeutics Market for Laser Surgery, by Country (2021 Vs 2024) 94
FIG. 53 Global Cryotherapy Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 95
FIG. 54 Global Cryotherapy Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 95
FIG. 55 Retinopathy Of Prematurity Therapeutics Market for Cryotherapy, by Country (2021 Vs 2024) 96
FIG. 56 Global anti-VEGF Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 97
FIG. 57 Global anti-VEGF Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 97
FIG. 58 Retinopathy Of Prematurity Therapeutics Market for anti-VEGF, by Country (2021 Vs 2024) 98
FIG. 59 Global Biologics (e.g. Bevacizumab) Market Revenue (USD Million) and Growth Rate (%), (2018 –
2030) 99
FIG. 60 Global Biologics (e.g. Bevacizumab) Market Revenue (USD Million) and Growth Rate (%), (2018 –
2030) 99
FIG. 61 Retinopathy Of Prematurity Therapeutics Market for Biologics (e.g. Bevacizumab), by Country (2021 Vs
2024) 100
FIG. 62 2022 Revenue Market Share (%) of Retinopathy Of Prematurity Therapeutics by End-User 102
FIG. 63 Global Hospitals Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 103
FIG. 64 Global Hospitals Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 103
FIG. 65 Retinopathy Of Prematurity Therapeutics Market for Hospitals, by Country (2021 Vs 2024) 104
FIG. 66 Global Ophthalmic Clinics Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 105
FIG. 67 Global Ophthalmic Clinics Market Revenue (USD Million) and Growth Rate (%), (2018 – 2030) 105
FIG. 68 Retinopathy Of Prematurity Therapeutics Market for Ophthalmic Clinics, by Country (2021 Vs 2024) 106
FIG. 69 Global Ambulatory Surgical Centers Market Revenue (USD Million) and Growth Rate (%), (2018 –
2030) 107
FIG. 70 Global Ambulatory Surgical Centers Market Revenue (USD Million) and Growth Rate (%), (2018 –
2030) 107
FIG. 71 Retinopathy Of Prematurity Therapeutics Market for Ambulatory Surgical Centers, by Country (2021 Vs
2024) 108
FIG. 72 Bayer AG Revenue Market Share (%) (2018-2022) 111
FIG. 73 Bayer AG R&D Investment (USD Million) (2019-2020) 112
FIG. 74 Bayer AG Net Sales, By Region (2019-2020) 112
FIG. 75 2018, 2022 and 2030 Revenue Market Share (%) of Retinopathy Of Prematurity Therapeutics by
Region 117
FIG. 76 North America Retinopathy Of Prematurity Therapeutics Market Share (%) by Country (2018-2030) 118
FIG. 77 North America Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection 119
FIG. 78 North America Retinopathy Of Prematurity Therapeutics Market Size by Indication 2022 and 2030 120
FIG. 79 North America Retinopathy Of Prematurity Therapeutics Market Size by Treatment Type 2022 and
2030 121
FIG. 80 North America Retinopathy Of Prematurity Therapeutics Market Size by End-User 2022 and 2030 122

23
FIG. 81 United States Retinopathy Of Prematurity Therapeutics Market Share % by Indication in 2022 123
FIG. 82 United States Retinopathy Of Prematurity Therapeutics Market Share % by Treatment Type in 2022 124
FIG. 83 United States Retinopathy Of Prematurity Therapeutics Market Share % by End-User in 2022 125
FIG. 84 Canada Retinopathy Of Prematurity Therapeutics Market Share % by Indication in 2022 126
FIG. 85 Canada Retinopathy Of Prematurity Therapeutics Market Share % by Treatment Type in 2022 127
FIG. 86 Canada Retinopathy Of Prematurity Therapeutics Market Share % by End-User in 2022 128
FIG. 87 Mexico Retinopathy Of Prematurity Therapeutics Market Share % by Indication in 2022 129
FIG. 88 Mexico Retinopathy Of Prematurity Therapeutics Market Share % by Treatment Type in 2022 130
FIG. 89 Mexico Retinopathy Of Prematurity Therapeutics Market Share % by End-User in 2022 131
FIG. 90 Europe Retinopathy Of Prematurity Therapeutics Market Share (%) by Country (2018-2030) 133
FIG. 91 Europe Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection 133
FIG. 92 Europe Retinopathy Of Prematurity Therapeutics Market Size by Indication 2022 and 2030 134
FIG. 93 Europe Retinopathy Of Prematurity Therapeutics Market Size by Treatment Type 2022 and 2030 135
FIG. 94 Europe Retinopathy Of Prematurity Therapeutics Market Size by End-User 2022 and 2030 136
FIG. 95 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Share (%) by Country (2018-2030) 142
FIG. 96 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection 142
FIG. 97 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by Indication 2022 and 2030 143
FIG. 98 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by Treatment Type 2022 and 2030 144
FIG. 99 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by End-User 2022 and 2030 145
FIG. 100 South America Retinopathy Of Prematurity Therapeutics Market Share (%) by Country (2018-2030) 150
FIG. 101 South America Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection 151
FIG. 102 South America Retinopathy Of Prematurity Therapeutics Market Size by Indication 2022 and 2030 152
FIG. 103 South America Retinopathy Of Prematurity Therapeutics Market Size by Treatment Type 2022 and
2030 153
FIG. 104 South America Retinopathy Of Prematurity Therapeutics Market Size by End-User 2022 and 2030 154
FIG. 105 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Share (%) by Country (2018-
2030) 157
FIG. 106 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection 158
FIG. 107 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by Indication 2022 and
2030 159
FIG. 108 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by Treatment Type 2022
and 2030 160
FIG. 109 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by End-User 2022 and
2030 161

24
TABLE 1 Market Snapshot 41
TABLE 2 Retinopathy Of Prematurity Therapeutics Market Revenue (USD Million) Comparison by Regions
(2018-2030) 43
TABLE 3 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) by Manufacturers (2018-2022) 53
TABLE 4 Global Retinopathy Of Prematurity Therapeutics Revenue Share by Manufacturers (2018-2022) 54
TABLE 5 Global Retinopathy Of Prematurity Therapeutics Market: Market Evaluation Framework 55
TABLE 6 Drivers For Retinopathy Of Prematurity Therapeutics Market: Impact Analysis 62
TABLE 7 Restraints For Retinopathy Of Prematurity Therapeutics Market: Impact Analysis 63
TABLE 8 Price Trend Analysis 79
TABLE 9 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) by Indication (2018-2030) 81
TABLE 10 Global Retinopathy Of Prematurity Therapeutics Revenue Share (%) by Indication (2018-2030) 81
TABLE 11 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) by Treatment Type (2018-
2030) 89
TABLE 12 Global Retinopathy Of Prematurity Therapeutics Revenue Share (%) by Treatment Type (2018-2030) 89
TABLE 13 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) by End-User (2018-2030) 101
TABLE 14 Global Retinopathy Of Prematurity Therapeutics Revenue Share (%) by End-User (2018-2030) 101
TABLE 15 Bayer AG Basic Information, Manufacturing Base, Sales Area and Its Competitors 110
TABLE 16 Bayer AG Revenue (USD Million), Gross Margin (%) and Market Share (%) (2018-2022) 111
TABLE 17 Global Retinopathy Of Prematurity Therapeutics Revenue (USD Million) by Region (2018- 2030) 117
TABLE 18 North America Retinopathy Of Prematurity Therapeutics Market by Country Revenue, 2018-2030 118
TABLE 19 North America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-
2030) 120
TABLE 20 North America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type
(2018-2030) 121
TABLE 21 North America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-
2030) 122
TABLE 22 United States Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-
2030) 123
TABLE 23 United States Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type
(2018-2030) 124
TABLE 24 United States Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-
2030) 125
TABLE 25 Canada Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-2030) 126
TABLE 26 Canada Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type (2018-
2030) 127
TABLE 27 Canada Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-2030) 128
TABLE 28 Mexico Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-2030) 129
TABLE 29 Mexico Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type (2018-
2030) 130
TABLE 30 Mexico Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-2030) 131
TABLE 31 Europe Retinopathy Of Prematurity Therapeutics Market by Country Revenue, 2018-2030 132
TABLE 32 Europe Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-2030) 134
TABLE 33 Europe Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type (2018-
2030) 135
TABLE 34 Europe Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-2030) 136
TABLE 35 Asia Pacific Retinopathy Of Prematurity Therapeutics Market by Country Revenue, 2018-2030 141
TABLE 36 Asia Pacific Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-
2030) 143

25
TABLE 37 Asia Pacific Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type
(2018-2030) 144
TABLE 38 Asia Pacific Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-
2030) 145
TABLE 39 South America Retinopathy Of Prematurity Therapeutics Market by Country Revenue, 2018-2030 150
TABLE 40 South America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Indication (2018-
2030) 152
TABLE 41 South America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by Treatment Type
(2018-2030) 153
TABLE 42 South America Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-User (2018-
2030) 154
TABLE 43 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market by Country Revenue, 2018-
2030 157
TABLE 44 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by
Indication (2018-2030) 159
TABLE 45 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by
Treatment Type (2018-2030) 160
TABLE 46 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market (USD Million) Size by End-
User (2018-2030) 161

26
1.1 Research Methodology
Our research involves the extensive use of both primary and secondary data sources for market surveys, estimates, and analyzing
forecasts. The report is based on an in-depth qualitative and quantitative analysis of the Retinopathy Of Prematurity Therapeutics
Market. We at CMR tend to draw on various study methods, including investigations, surveys, secondary data, and market
observation. Our approach helps build a better market consensus view for size, shape, and industry trends within each segment.
We carefully factor in industry trends and actual developments for identifying key growth factors and the future course of the
market. The gathered data has been interpreted and analyzed to provide a conclusion.
The complete process involves the study of various factors, such as market scenarios, government policies, competitive
environment, historical data, current trends, technological advancements, and progress in related industries, along with threats
and challenges.

27
1.1.1 Primary Research
The primary research involves sources from the entire value chain, i.e., from supply to demand side players. The efforts include
contacting participants through emails, telephonic conversations, referrals, professional networks, and formal interactions. These
players were interviewed to obtain qualitative and quantitative information regarding the Retinopathy Of Prematurity
Therapeutics Market. Primarily, the interviews were conducted to design the scope of the report to identify segment analysis.
Our primary research interviews and discussion panel comprises vital opinion leaders, industry experts, manufacturers, and
organizations. We have pooled these experts to gather first-hand insights into the market studied. Moreover, market surveys
were performed to get insights into market trends and competitive analysis. Primary research was conducted to validate data
that had been gained by doing secondary research and to fill the data gaps after the secondary research process.
Thus, the primary research study helps us to identify segmentation types, product price range, product applications, major players
involved, raw material suppliers, downstream demand, industry status, and outlook. We analyze respective risks, influence
factors, opportunities, market barriers, industry trends, and key player strategies associated with Retinopathy Of Prematurity
Therapeutics Market by performing primaries with an exhaustive list of participants.
FIG. 1 Primary Research Method
Extensive Primary Research Helps Us to:
• Validate data findings and strengthens research proceeds
• Develop an in-depth market understanding
• Supply authentic information about market size, share breakdown, growth, and forecast

28
1.1.2 Modes of Primary Research:
We have conducted primary research involving direct interaction with the source, usually a customer or prospective customer.
Methods used while doing primary research includes Interviews, Surveys, Focus Group, etc.
FIG. 2 Market Research Process
1.2 Secondary Research Methodology:
In secondary research, we collect data on the global Retinopathy Of Prematurity Therapeutics market through White Papers,
Case Studies, Blogs, Reference Clients, News, Articles, Press Releases, Research Reports, Annual Reports, Company Investor
Presentations, Scientific Journals, National Customs, Industry Associations, and the company's filings with the SEC. Sources and
approaches differ from market to market and product to product. We also have paid data sources like Hoovers, Bloomberg
BusinessWeek, Factiva (Dow Jones), Statista, Reuters, One Source, and more. After conducting secondary research, we conduct
primary research by interacting with industry experts such as VPs, product managers, and various industry consultants. The
number of interviews conducted depends on market size and the availability of market recovery data.
Based on the understanding of requirements, we conducted secondary research to identify the segment specifications and
qualitative and quantitative data along with the factors responsible for the growth of the global Retinopathy Of Prematurity
Therapeutics market. Moreover, quantitative and qualitative data were also extracted from paid databases, which proved to be
useful for in-depth technical study of the market. Secondary research is used to identify and collect information useful for the
extensive, technical, market-oriented, and table tops survey of the market. It was used to obtain important information about
the top companies, market classification, and segmentation according to industry trends to the bottom-most levels, and key
developments related to market and technology perspectives. Secondary research has mainly been applied to obtain critical
information about the industry’s supply chain, the market downstream buyers, technical dynamics development trends.
Furthermore, it also helps to gain insight on the key vendors of this market, and market classification & segmentation according
to the industry trends, regional markets, and key developments from a market and business-oriented perspective.

29
FIG. 3 Source of Secondary Research
1.3 Market Estimation
Top-down and bottom-up approaches have been implemented to validate the Retinopathy Of Prematurity Therapeutics market
size estimation. The market estimations in this report are based on the marketed sale price of products. The percentage
breakdown of regions and segments are derived based on the data gathered from primary and secondary sources, based upon
the weightage assigned to the individual segment.
The competitive scenario has been understood by identifying major players involved in the market. The company's revenue for
the Retinopathy Of Prematurity Therapeutics market has been estimated through secondary and validated through primary
research. We have done the company's secondary research through annual reports, news articles, and other trusted sources.
Primary research included interviews of key opinion leaders and industry experts such as experienced front-line staff, directors,
CEOs, and marketing executives.
This research studies includes all the associated factors impacting market growth. This data is combined and added with detailed
inputs and analysis, which is presented in this report.

30
1.3.1 Top-Down Method
FIG. 4 Top-Down Method
1.3.2 Bottom-Up Method
FIG. 5 Bottom-Up Method

31
1.3.3 Data Triangulation
After completing market engineering with calculations for market statistics, market size estimations, market forecasting, market
breakdown, and other data gathering, extensive primary research was conducted to gather information and verify and validate
the critical numbers arrived at. The data was triangulated by studying various factors and trends from both, the demand and
supply sides. Along with this, the market size was validated using the top-down and bottom-up approach.
FIG. 6 Data Triangulation

32
1.4 Questionnaire
At Cognitive Market Research, we have designed questionnaire focused on Retinopathy Of Prematurity Therapeutics Market for
the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Retinopathy
Of Prematurity Therapeutics industry experts of entire value chain, located across the globe. This study help us to gather accurate
quantitative and qualitative data for the final report.

33

34
2.1 Global Retinopathy Of Prematurity Therapeutics Industry Introduction

35
2.2 Objectives of the Study
• Our objective for the Retinopathy Of Prematurity Therapeutics market is to help in making imperative business
decisions, securing investments, determining new business opportunities in the market. Further, the report helps to
analyze overall marketing needs of customers, and avoiding business failures
• To know the potential market size and growth rate before launching a new product line. The report in a way help in
designing R&D budget wisely by estimating maximum total profit
• To identify the Retinopathy Of Prematurity Therapeutics market dynamics, industrial insights, and economic
progression for critical information about the market conditions and specific business landscape
• To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards
with various external factors impacting the market growth
• To create a strong foundation for building a strategy and foster insight into market conditions so that market players
can make better business decisions. Besides, our aim is to provide complete portfolio of the major players involved the
market
• To define the scope which will further help in creating new products that will surpass the gap between current offerings
and customers’ needs
• To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that
plays an integral role in shaping market behavior
• To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the
total market.
2.3 USP of the Report
Cognitive market research is a market research, analysis and solutions focused company that provides clients with strategic and
tactical support to draw informed business conclusions. We are a dedicated and enthusiastic group of people who firmly believe
in doing our best in what we do, and we never back down from any challenge.
Cognitive Market Research provides coverage, analysis, information, statistics and reports on global and regional markets,
industries, sectors and domains including pharmaceuticals, chemicals and materials, technology and media, food and beverages,
packaging and consumer and other industries. We provide a 360-degree view of the market and provide accurate forecasts, and
also cover the competitive landscape, providing detailed market segmentation, key trends and strategic recommendations to
keep our clients ahead of the competition.
We broadly categorize our products into custom market research and syndicated market research reports. A syndicated research
report covers data, information and analysis on a subject or subject that may benefit one or more businesses or individuals. Topics
or headlines may vary by macro industry or micro market level. We offer unique report titles which cover the entire landscape of
the specific industry from a host of industry verticals.

36
2.4 Who is this report for?
The research study and report are been made exclusively for an institution or person who is strategizing to build a business or
strategically wants to expand certain portfolio. This report will help in analyzing complete market scenario across the globe who
wish to expand its current business or is willing to invest in some profitable sector. This report will prove beneficial for person or
an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements.
The environment is constantly changing, in such scenario this report will help in understanding market parameters through 360-
degree view.
The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development
managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can
also leverage our report to understand market.
2.5 Regional Fragmentation
NA:
➢ U.S., Canada, Mexico
EU:
➢ Germany, UK, Italy, France, Spain, Switzerland, Sweden, Rest of EU
APAC:
➢ China, Japan, India, South Korea, Australia, Philippines, Vietnam, Malaysia, Rest of APAC
LA:
➢ Brazil, Chile, Argentina, Colombia, Peru, Rest of Latin America
MEA:
➢ Saudi Arabia, UAE, Egypt, South Africa, Iraq, Kuwait, Morocco, Others

37
2.6 Report Duration
Note: *The complete report is been projected in USD Dollars. In the process of analysis, findings from other currency is been
converted to USD Dollars
**All the estimations in terms of volume and revenue are presented in Units and USD Million respectively.
2.7 List of Stakeholders
➢ Raw material suppliers
➢ Manufacturers and Distributors
➢ OEM’s
➢ Government and financial institutions
➢ Technology investors
➢ Venture capitalists
➢ Associations, organizations, forums, and alliances
➢ End-users
2023-2030
2022
2018-2022

38
3.1 Global Retinopathy Of Prematurity Therapeutics Market, 2018 – 2030, (USD Million)
The Global Retinopathy Of Prematurity Therapeutics Market is valued at USD XX Million in 2018 and is expected to reach USD
XX Million by the end of 2030, growing at a CAGR of XX% between 2023 and 2030.
FIG. 7 Global Retinopathy Of Prematurity Therapeutics Market, 2018 – 2030, (USD Million)
Source: Cognitive Market Research

39
3.2 Global Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity Analysis
FIG. 8 Global Retinopathy Of Prematurity Therapeutics Value, Absolute & Opportunity
Analysis
3.3 Global Retinopathy Of Prematurity Therapeutics Market Y-o-Y Growth Projection by Region
(2023 - 2030)
FIG. 9 Global Retinopathy Of Prematurity Therapeutics Market, Y-o-Y Growth Projection
(2023-2030)

40

41
3.4 Global Retinopathy Of Prematurity Therapeutics Market: Snapshot
TABLE 1 Market Snapshot
Retinopathy
Of
Prematurity
Therapeutics
Market
2018 2022 2030
Global
Revenue
(USD
Million)
xx xx xx
CAGR (2023
– 2030)
xx%
Key
Indication
Segment
(Revenue
Share)
Extra-retinal Fibrovascular
Proliferation:xx%
Partial Retinal Detachment:xx%
Total Retinal Detachment:xx%
Proliferation:xx%
Proliferation:xx%
Key
Treatment
Type
Segment
(Revenue
Share)
Oxygen therapies:xx%
Laser Surgery:xx%
Cryotherapy:xx%
anti-VEGF:xx%
Biologics (e.g.
Bevacizumab):xx%
Laser Surgery:xx%
Cryotherapy:xx%
anti-VEGF:xx%
Biologics (e.g.
Bevacizumab):xx%
Laser Surgery:xx%
Cryotherapy:xx%
anti-VEGF:xx%
Biologics (e.g.
Bevacizumab):xx%
Key End-User
Segment
(Revenue
Share)
Hospitals:xx%
Ophthalmic Clinics:xx%
Ambulatory Surgical
Centers:xx%
Hospitals:xx%
Ambulatory Surgical
Centers:xx%
Hospitals:xx%
Ambulatory Surgical
Centers:xx%
Key Regional
Segment
(Revenue
Share)
North America: xx%
Europe: xx%
Asia Pacific: xx%
Latin America: xx%
Middle East and Africa: xx%
North America: xx%
Europe: xx%
Asia Pacific: xx%
Latin America: xx%
North America: xx%
Europe: xx%
Asia Pacific: xx%
Latin America: xx%

42
Driver
Restraint
Opportunity
Trend

43
4.1 Product Overview and Scope of Retinopathy Of Prematurity Therapeutics Market
4.2 Global Retinopathy Of Prematurity Therapeutics Revenue Market by Regions (2018-2030)
TABLE 2 Retinopathy Of Prematurity Therapeutics Market Revenue (USD Million) Comparison by
Regions (2018-2030)
Regions 2018 2022 2030 Market Share
(%)
2030
CAGR (%)
(2023-2030)
North America XX XX XX XX Xx
Europe XX XX XX XX Xx
Asia Pacific XX XX XX XX Xx
Latin America XX XX XX XX Xx
Middle East and Africa XX XX XX XX Xx
Total XX XX XX XX XX
FIG. 10 Global Retinopathy Of Prematurity Therapeutics Revenue Market Share (%) by Regions
in 2018, 2022, 2030

Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research

Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research

Recommended

Recommended

More Related Content

Similar to Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research

Similar to Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research (12)

More from Cognitive Market Research

More from Cognitive Market Research (15)

Recently uploaded

Recently uploaded (20)

Global Retinopathy Of Prematurity Therapeutics Market Report 2023 - Cognitive Market Research